By Hendra Lukman 
Duke University researchers have identified a crucial enzyme, kinase STK17B, involved in iron regulation within multiple myeloma (MM) cancer cells. This groundbreaking discovery not only demonstrates the enzyme’s ability to directly eliminate these cancerous cells but also significantly amplifies the efficacy of current treatment regimens for the disease. The findings, published on September 12 in the esteemed journal Blood, offer a promising new avenue for combating this persistent and often relapsing blood cancer.
Understanding Multiple Myeloma: A Persistent Challenge
Multiple myeloma is a complex and currently incurable malignancy affecting plasma cells, a vital component of the immune system responsible for producing antibodies to combat infections. In patients with MM, these plasma cells proliferate uncontrollably within the bone marrow. This unchecked growth leads to a cascade of debilitating consequences: displacement of healthy blood-forming cells, the production of excessive and abnormal antibodies that can impair immune function, damage to critical organs like the kidneys, and the development of painful bone lesions. MM represents a significant portion of all blood cancer diagnoses, accounting for nearly 10 percent. While advancements in targeted therapies have provided avenues for managing the disease, the growing incidence of symptom relapse and the emergence of drug-resistant forms of multiple myeloma underscore the urgent need for innovative treatment strategies.
The Role of Ferroptosis in Cancer Cell Survival
The precise etiology of multiple myeloma remains incompletely understood. However, a consistent observation in MM research has been the frequent suppression of ferroptosis, a naturally occurring form of programmed cell death intrinsically linked to the accumulation of excess iron within cells. Ferroptosis is a meticulously orchestrated process where excessive iron triggers oxidative damage to the delicate lipid membranes of cells, ultimately leading to their disintegration. In the context of cancer, this cellular self-destruction mechanism is often circumvented.
"Cancer cells live like there is no tomorrow," explained Mikhail Nikiforov, a professor of pathology and biomedical engineering at Duke University and a lead author of the study. "They accumulate iron at levels that would normally be toxic and tear cells apart, but that wasn’t what we observed. Instead, these cancer cells adapted to resist the type of cell death triggered by iron overload, and the mechanisms behind this suppression were largely unknown." This adaptation allows cancer cells to thrive in an environment that would be lethal to healthy cells, posing a significant hurdle for therapeutic interventions.
Unraveling the Mechanism: STK17B as the Key Regulator
For years, the scientific community has sought to elucidate the precise molecular machinery that enables cancer cells to evade ferroptosis. The Duke University research team, led by Professor Nikiforov, has now provided a definitive answer by pinpointing kinase STK17B as the pivotal enzyme responsible for suppressing ferroptosis in multiple myeloma cells. STK17B, traditionally known for its roles in regulating cell death pathways and T-cell activation, has now been revealed to play a critical, albeit previously unrecognized, role in maintaining cellular iron homeostasis. The researchers observed that STK17B acts as a crucial modulator, balancing the expression of proteins that either promote (pro-ferroptotic) or inhibit (anti-ferroptotic) this iron-induced cell death pathway.
The significance of STK17B’s role is further underscored by its correlation with patient outcomes. "Elevated levels of STK17B are associated with poor overall survival in MM patients," stated Professor Nikiforov. "STK17B expression is also especially pronounced in relapsed cases of the disease, underscoring its role in therapy resistance." This observation provides a direct link between the enzyme’s activity and the aggressive nature and recalcitrance of multiple myeloma to treatment, suggesting that targeting STK17B could be a potent strategy to overcome these challenges.
A Novel Therapeutic Strategy: Inhibiting STK17B
The research team leveraged a specially developed compound, created by Timothy Willson, the Harold Kohn Distinguished Professor in Open Science Drug Discovery at the UNC Eshelman School of Pharmacy. This innovative compound was instrumental in inhibiting STK17B’s regulatory influence over iron accumulation within the cancer cells. By blocking STK17B’s activity, the researchers successfully reactivated the ferroptosis pathway, leading to the targeted destruction of multiple myeloma cells.
Beyond its direct cytotoxic effect, the inhibition of STK17B demonstrated a synergistic effect with existing therapies. The study observed that rendering cancer cells more susceptible to ferroptosis through STK17B inhibition also made them significantly more vulnerable to conventional multiple myeloma treatments. This suggests that combining STK17B inhibitors with current standard-of-care regimens could lead to more potent and effective therapeutic outcomes, potentially overcoming drug resistance mechanisms.
Pre-clinical Validation: Promising Results in Mouse Models
To validate their findings in a living system, Professor Nikiforov’s team conducted pre-clinical trials using an orally administered version of the STK17B inhibitor in mouse models of multiple myeloma. The results were highly encouraging. The compound not only induced ferroptosis by promoting increased iron uptake in the cancer cells but also led to a significant reduction in tumor growth. These findings provide compelling evidence for the therapeutic potential of targeting STK17B in a clinical setting.
"These findings establish that STK17B is a critical safeguard protecting MM cells from the toxic consequences of their iron independence," Professor Nikiforov asserted. "Inhibiting this kinase holds much promise as a therapeutic strategy." The ability to orally administer the inhibitor further enhances its potential for widespread clinical application, offering a more convenient and patient-friendly treatment option compared to intravenous therapies.
Future Directions and Broader Implications
The implications of this research extend beyond the immediate application to multiple myeloma. The team is actively pursuing further development, focusing on optimizing the formulation of the inhibitor for enhanced delivery and efficacy. Recognizing the significant therapeutic potential, they have filed a provisional patent based on their discoveries, with the ultimate goal of commercializing this novel therapy.
Furthermore, the researchers are keen to explore the broader applicability of their findings to other cancer types. "Many other types of cancer cells are also resistant to ferroptosis," Professor Nikiforov noted. "We’re curious to see how this inhibitor could improve therapies for other tumors outside of multiple myeloma." This suggests that STK17B inhibition could represent a versatile therapeutic strategy with the potential to impact a wide range of malignancies that exhibit similar resistance mechanisms.
The research was supported by a consortium of prestigious funding bodies, including the National Institutes of Health (NIH) and the National Cancer Institute (NCI) through various grants (NCI R01CA264984 to M.A.N., NCI R21CA267275 and 17R21CA280499 to Y. K., NHLBI R01HL168492 to E.A.L.), the Duke Cancer Institute (NCI P30CA014236), and the Paula and Rodger Riney Foundation (L.H.B.). Additional support was provided by the Structural Genomics Consortium (SGC), a registered charity receiving funds from a multitude of pharmaceutical and governmental organizations, including Bayer AG, Boehringer Ingelheim, Bristol Myers Squibb, Genentech, Genome Canada, the EU/EFPIA/OICR/McGill/KTH/Diamond Innovative Medicines Initiative 2 Joint Undertaking (EUbOPEN grant 875510), Janssen, Merck KGaA, Pfizer, and Takeda. Funding was also partially derived from the NIH Illuminating the Druggable Genome grant (1U24DK116204-01). This extensive collaborative effort highlights the significant scientific and financial investment dedicated to advancing cancer research.
The discovery of STK17B’s role in multiple myeloma and its susceptibility to targeted inhibition represents a significant leap forward in understanding and potentially treating this challenging disease. The research not only offers a direct method for eliminating cancer cells but also provides a means to enhance the effectiveness of existing therapies, paving the way for more potent and durable treatment responses for patients battling multiple myeloma and potentially other ferroptosis-resistant cancers.